Outline of signing ceremony
On Sunday, June 28, 2015, from 10 a.m., three institutions, Lymphotec Inc., the 307th Hospital of Chinese People’s Liberation Army, and Beijing Longbao Science & Technology Development Co., Ltd., held a signing ceremony for a contract for a joint clinical study on activated autologous lymphocyte therapy at the Diaoyutai State Guesthouse in the City of Beijing. Teruaki Sekine, Chairman of the Board of Directors, who developed the culture method for activated autologous lymphocyte (Sekine Method), and Hiroyuki Funamoto, President and CEO of Lymphotec Inc.; Chen Hu, Director of the 307th Hospital of Chinese People’s Liberation Army; and Zhang Fengchun, President of Beijing Longbao Science & Technology Development Co., Ltd. attended the signing ceremony, and the representatives from the three institutions greeted each other with a handshake and smile after signing on the contract for joint clinical study.
Details of joint clinical study
Lymphotec examines effects of the activated autologous lymphocyte therapy on prevention of recurrence of cancer after treatment in cancer patients (hepatoma or glioblastoma) at hospitals in the City of Beijing in cooperation with the 307th Hospital of Chinese People’s Liberation Army and Beijing Longbao Science & Technology Development Co., Ltd. Lymphotec conducts culture of activated autologous lymphocytes using blood collected from patients, the 307th Hospital of Chinese People’s Liberation Army conducts treatment with the activated autologous lymphocytes in cancer patients, and Beijing Longbao Science & Technology Development Co., Ltd. provides administrative operation of a lymphocyte culturing facility in the City of Beijing. More specifically, the activated autologous lymphocyte is administered 6 times biweekly to 30 hepatoma patients and 10 glioblastoma patients after surgery to remove the cancer. After the 4th and 6th administrations, the quality of life (QOL), blood biochemical parameters, and images of the focal sites will be examined to evaluate the effects of the activated autologous lymphocyte on prevention of recurrence of cancer.